Skip to main content

Table 3 Clinical factors associated with SII

From: Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma

Variables Low SII (n = 29) High SII (n = 29) P value
Age    0.599
  < 60 15 (51.7) 13(44.8)  
  ≥ 60 14(48.3) 16(55.2)  
Sex    0.640
 Male 26(89.7) 27(93.1)  
 Female 3(10.3) 2(6.9)  
Child Pugh score    0.401
 A5 18(62.1) 21(72.4)  
 A6 11(37.9) 8(27.6)  
ALBI grade    1.000
 1 13(44.8) 13(44.8)  
 2 16(55.2) 16(55.2)  
AFP (ng/mL)    0.597
  < 400 14(48.3) 12(41.4)  
  ≥ 400 15(51.7) 17(58.6)  
PIVKA-II (mAU/mL)    0.240
  < 1000 10(34.5) 6(20.7)  
  ≥ 1000 19(65.5) 23(79.3)  
NLR    0.000
  < 2.4 23(79.3) 5(17.2)  
  ≥ 2.4 6(20.7) 24(82.8)  
PLR    0.000
  < 108 12(79.3) 6(20.7)  
  ≥ 108 6(20.7) 23(79.3)  
BCLC stage    0.036
 B 11(37.9) 4(13.8)  
 C 18(62.1) 25(86.2)  
Vascular invasion    1.000
 No 20(69.0) 20(69.0)  
 Yes 9(31.0) 9(31.0)  
Extrahepatic metastases    0.104
 No 14(48.3) 8(37.6)  
 Yes 15(51.7) 21(72.4)  
  1. Values are presented as number (%) of patients
  2. AFP alpha-fetoprotein, ALBI albumin–bilirubin, BCLC Barcelona Clinic Liver Cancer, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, PIVKA protein induced by vitamin K absence or antagonist, SII systemic immune-inflammation index